Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)

被引：8
|
作者：
Dondorf, Sabine
Schrader, Alexandra [1 ]
Herling, Marco
机构：
[1] Univ Cologne, Lab Lymphocyte Signaling & Oncoproteome, Dept Internal Med 1, Ctr Integrated Oncol CIO Koln Bonn, D-50931 Cologne, Germany
来源：
JOURNAL OF BIOLOGICAL CHEMISTRY | 2015年 / 290卷 / 16期
关键词：
INHIBITORS;
D O I：
10.1074/jbc.L115.644641
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
6
引用
收藏
页码：10568 / 10569
页数：2
相关论文
共 50 条
  • [31] T-cell prolymphocytic leukemia
    Dearden, CE
    MEDICAL ONCOLOGY, 2006, 23 (01) : 17 - 22
  • [32] T Cell Prolymphocytic Leukemia (T-PLL): Cutaneous Involvement in an Uncommon Leukemia
    Kakkar, Naveen
    Calton, Nalini
    John, M. Joseph
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (03) : 573 - 574
  • [33] T Cell Prolymphocytic Leukemia (T-PLL): Cutaneous Involvement in an Uncommon Leukemia
    Naveen Kakkar
    Nalini Calton
    M. Joseph John
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 573 - 574
  • [34] A Phase Ib Pilot Study of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL)
    Kadia, Tapan M.
    Ravandi, Farhad
    Borthakur, Gautam
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Adewale, Lade
    Pierce, Sherry A.
    Jain, Nitin
    Ferrajoli, Alessandra
    Wierda, William G.
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [35] Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR
    Murthy, Hemant S.
    Ahn, Kwang Woo
    Estrada-Merly, Noel
    Gowda, Lohith
    Dholaria, Bhagirathbhai
    Bal, Susan
    Alkhateeb, Hassan B.
    Jagadeesh, Deepa
    Oran, Betul
    Nakamura, Ryotaro
    Scott, Bart L.
    Sauter, Craig S.
    Foss, Francine M.
    Kharfan-Dabaja, Mohamed A.
    Saber, Wael
    BLOOD, 2020, 136
  • [36] Venetoclax combined with cladribine in patients with relapsed/refractory (R/R) T-cell prolymphocytic leukemia (T-PLL).
    Arani, Naszrin
    Jammal, Nadya
    Geppner, Alexis
    Kim, Kunhwa
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience
    Aoki, Etsuko
    Jain, Preetesh
    Ferrajoli, Alessandra
    Estrov, Zeev
    Keating, Michael
    O'Brien, Susan M.
    Wierda, William G.
    Jain, Nitin
    Thompson, Philip A.
    Jabbour, Elias
    Pierce, Sherry
    Hosing, Chitra
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2016, 128 (22)
  • [38] A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation
    Mamontov, Polina
    Eberwine, Ryan A.
    Perrigoue, Jackie
    Das, Anuk
    Friedman, Joshua R.
    Mora, J. Rodrigo
    PLOS ONE, 2019, 14 (04):
  • [39] CPI-818: a selective interleukin-2-inducible T-cell kinase (ITK) inhibitor has clinical activity in dogs with spontaneous T cell lymphoma
    Thamm, D.
    Weishaar, K.
    Das, S.
    Madriaga, A.
    Hill, C.
    Flicker, F.
    Wolfe, B.
    Ng, P.
    Hotson, A.
    Miller, R.
    Buggy, J.
    Janc, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E5 - E5
  • [40] Interleukin-2-inducible T Cell Kinase (Itk) Network Edge Dependence for the Maturation of iNKT Cell
    Qi, Qian
    Xia, Mingcan
    Bai, Yuting
    Yu, Sanhong
    Cantorna, Margherita
    August, Avery
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (01) : 138 - 146
12345